Literature DB >> 16096743

[The aftercare principle for metastasizing prostate cancer. Few diagnostics, much support].

K Heine1, J M Wolff.   

Abstract

For advanced prostate cancer - not including intermittent strategies - the patient is in continual treatment. The effect of the therapy must be controlled so that its failure can be determined as soon as possible and a new regimen started. As in most cases the progression of the disease can not be stopped, the aim of the therapy is to provide the patient with the best possible quality of life. In order to carry out therapy, if possible in the patient's usual environment, supportive therapies should be used, such as compensation for anaemia or pain therapy as required. Skeletal complications can be prophylactically treated by the use of biphosphonates.

Entities:  

Mesh:

Year:  2005        PMID: 16096743     DOI: 10.1007/s00120-005-0885-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  44 in total

1.  Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Authors:  D P Petrylak; H I Scher; Z Li; C E Myers; N L Geller
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

2.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

3.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.

Authors:  C J Ercole; P H Lange; M Mathisen; R K Chiou; P K Reddy; R L Vessella
Journal:  J Urol       Date:  1987-11       Impact factor: 7.450

4.  Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice.

Authors:  G Stüben; O Thews; C Pöttgen; K Knühmann; P Vaupel; M Stuschke
Journal:  J Cancer Res Clin Oncol       Date:  2001       Impact factor: 4.553

5.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

6.  Alendronate for the treatment of osteoporosis in men.

Authors:  E Orwoll; M Ettinger; S Weiss; P Miller; D Kendler; J Graham; S Adami; K Weber; R Lorenc; P Pietschmann; K Vandormael; A Lombardi
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

7.  Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy.

Authors:  V Rudat; A Dietz; O Schramm; C Conradt; H Maier; M Flentje; M Wannenmacher
Journal:  Radiother Oncol       Date:  1999-11       Impact factor: 6.280

8.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

9.  The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience.

Authors:  H Frommhold; R Guttenberger; M Henke
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

10.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

Authors:  David P Dearnaley; Matthew R Sydes; Malcolm D Mason; Mark Stott; Christopher S Powell; Anne C R Robinson; Peter M Thompson; Leslie E Moffat; Sharon L Naylor; Mahesh K B Parmar
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

View more
  1 in total

Review 1.  [Diagnostic work-up of bone metastases of genitourinary tumors and their treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006].

Authors:  L Weissbach
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.